

Pharmaids Pharmaceuticals Limited.

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

Email: mailpharmaids@yahoo.co.in, Website: www.pharmaids.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES AS ON 30.09.2016

(Rs. In lakhs)

Particulars		As on 30.09.2016 Un-Audited	As on 31.03.2016 Audited
A	EQUITY AND LIABILITY		
1	SHARE HOLDERS' FUNDS:		
	(a) Share Capital	336.31	336.31
	(b) Reserves and Surplus	(211.15)	(204.50)
	Sub Total - Shareholders Fund	125.16	131.81
2	Share application money pending allotment	0.00	0.00
3	Minority Interest	0.00	0.00
4	Non-Current Liabilities		
	(a) Long term Borrowings	23.55	27.31
	(b) Deferred Tax (Net)	2.72	2.72
	(c) Other Long term Liabilities	0.00	0.00
	(d) Long Term Provisions	0.00	0.00
	Sub-Total - Non Current Liabilities	26.27	30.03
5	Current Liabilities		
	(a) Short Term Borrowings	29.65	20.52
	(b) Trade Payables	38.67	44.49
	(c) Other Current Liabilities	2.13	2.87
	(d) Short Term Provisions	0.00	0.00
	Sub-Total - Current Liabilities	70.45	67.88
	TOTAL EQUITY AND LIABILITY	221.88	229.72
B	ASSETS		
1	Non-Current Assets		
	(A) Fixed Asset	39.76	43.68
	(b) Non Current Investment	0.00	0.00
	(c) Deferred Yax Asset (Net)	0.00	0.00
	(d) Long term Loans and Advances	26.59	32.20
	(e) Other Non-Current Assets	0.01	0.01
	Sub-Total Non-Current Assets	66.36	75.89
2	Current Assets		
	(a) Current Investments	0.00	0.00
	(b) Inventories	20.35	28.80
	(c) Trade Receivables	116.90	107.42
	(d) Cash and Cash equivalents	18.27	17.61
	(e) Short Term Loans and Advances	0.00	0.00
	(f) Other Current Assets	0.00	0.00
	Sub-Total Current Assets	155.52	153.83
	TOTAL	221.88	229.72

For PHARMAIDS PHARMACEUTICALS LIMITED

For Pharmaids Pharmaceuticals Limited

PLACE : HYDERABAD

DATE : 14.11.2016

Dr. Ghisulal Jain
Chairman & Managing Director

note on report given date
FOR RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

B. Ramkishan Kumar
(B. RAMKISHAN KUMAR)
PARTNER
M.No: 200304

4-4-211/212/11-12, Inderbagh, Hyderabad – 500 095.

CIN No. L52520TG1989PLC009679

2016

(Arnt in lakhs)

S. No	Particulars	QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
		Un-Audited			Un-Audited		Audited
1	Income from Operations						
	(a) Net Sales/Income from operations	31.18	34.20	31.66	65.38	89.15	168.45
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	0.00
	Total Income from Operations	31.18	34.20	31.66	65.38	89.15	168.45
2	Expenses						
	a. Consumption of raw materials	1.29	3.19	5.06	4.48	10.16	0.00
	b. Purchases of stock-in-trade	14.41	10.23	21.18	24.64	42.79	114.51
	c. Increase/decrease in stock in trade and WIP	(0.73)	7.95	(4.91)	7.22	0.66	0.89
	d. Employees Cost	5.48	5.98	6.07	11.46	11.25	20.30
	e. Depreciation	1.96	1.96	2.52	3.92	4.94	10.37
	f. Other expenditure	12.09	5.41	11.57	17.50	24.00	67.29
	Total	34.50	34.72	41.49	69.22	93.80	213.36
	(Any item exceeding 10% of the total expenditure to be shown separately)	0.00	0.00	0.00	0.00	0.00	0.00
3	Profit / (Loss) from Operations before other Income, finance	(3.32)	(0.52)	(9.83)	(3.84)	(4.65)	(44.91)
4	Other Income	0.00	0.04	4.50	0.04	4.50	4.57
5	Profit / (Loss) from Ordinary activities before finance costs	(3.32)	(0.48)	(5.33)	(3.80)	(0.15)	(40.34)
6	Finance Cost	1.48	1.37	0.81	2.85	0.84	2.87
7	Profit / (Loss) from Ordinary activities after finance costs but	(4.80)	(1.85)	(6.14)	(6.65)	(0.99)	(43.21)
8	Exceptional Items - Expenditure / (Income)	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from Ordinary Activities before tax	(4.80)	(1.85)	(6.14)	(6.65)	(0.99)	(43.21)
10	Tax expense						
	a) Provision for Taxation	0.00	0.00	0.00	0.00	0.00	0.00
	b) Provision for Deferred tax	0.00	0.00	0.00	0.00	0.00	3.45
	c) MAT Credit	0.00	0.00	0.00	0.00	0.00	0.00
11	Net Profit (+)/ Loss (-) from ordinary activities after tax	(4.80)	(1.85)	(6.14)	(6.65)	(0.99)	(39.76)
12	Extraordinary items (net of tax expense Rs.Nil)	0.00	0.00	0.00	Nil	Nil	Nil
13	Net Profit (+)/Loss (-) for the period	(4.80)	(1.85)	(6.14)	(6.65)	(0.99)	(39.76)
14	Paid-up equity share capital	336.31	336.31	336.31	336.31	336.31	336.31

	a) Basic	(0.14)	(0.06)	(0.18)	(0.20)	(0.03)	(1.17)
	b) Diluted	(0.14)	(0.06)	(0.18)	(0.20)	(0.03)	(1.17)
17	Earnings Per Share (after extra-ordinary items - not annualised)						
	a) Basic	(0.14)	(0.06)	(0.18)	(0.20)	(0.03)	(1.17)
	b) Diluted	(0.14)	(0.06)	(0.18)	(0.20)	(0.03)	(1.17)

1. The above un-audited Financial Results of the company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 14th November, 2016.

2) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only.

3) There were no investor complaints pending at the beginning of the quarter and no investor complaint was received and remained pending at the end of the said quarter

4) Figures for the previous period have been re-grouped or re-arranged wherever considered necessary.

5) Provision for Income Tax and Deferred Tax will be made at the end of the Financial year.

PLACE : HYDERABAD

DATE : 14.11.2016

For PHARMAIDS PHARMACEUTICALS LIMITED

For Pharmaids Pharmaceuticals Limited

Sd/- Dr. Ghisulal Jain

Chairman & Managing Director

Managing Director

Vide our Report of even date
For RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

B. Ramesh Kumar 14/11/16
(B. RAMESH KUMAR)
PARTNER
M.No: 200304





RAKESH S JAIN & ASSOCIATES
CHARTERED ACCOUNTANTS

B. Ramesh Kumar (Mob) : +91-9849025641
E-mail : rsjainassociates@rediffmail.com

14-6-191, Nagar Khana, Begum Bazar,
Hyderabad - 500 012. (T.S.) INDIA,

Date :

LIMITED REVIEW REPORT

To
The Board of Directors,
M/s Pharmaids Pharmaceuticals Limited,
Hyderabad.

We have reviewed the accompanying statement of unaudited financial results of M/s **Pharmaids Pharmaceuticals Limited** ("the Company") for the quarter ended **30th September 2016** except for the disclosures regarding Public Shareholding and Promoter Group Shareholding which has been traced from disclosures made by the management and has not been audited by us. This statement is the responsibility of company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on these Financial Statements based on our review.

We conducted our review in accordance with the **Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Auditor of the Entity"** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Management has informed to us being quarterly closing, the company has not accounted for taxes on income as required under AS-22 i.e. Deferred Tax and Income Tax, the same will be considered at the time of year end.

Based on our review conducted as above and subject to the points mentioned above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI(Listing obligations and Disclosure Requirements) Regulations,2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.